Ovid Tx appoints CMO and head of epilepsy research

8 February 2023

US neurological diseases specialist Ovid Therapeutics (Nasdaq: OVID) is expanding its medical and development team with the respective appointments of industry veterans, Dr Manoj Malhotra as its chief medical officer (CMO) and Dr Toshiya Nishi as its head of epilepsy research.

Immediately prior to joining Ovid, Dr Malhotra served in the neurology business group at the US subsidiary of Japan’s Eisai (TYO: 4523). During his tenure, he led global medical affairs for their epilepsy and multiple sclerosis businesses. Dr Malhotra was also a global senior medical director at Mallinckrodt Pharmaceuticals Autoimmune and Rare Disease Unit, and he held senior roles at Takeda Pharmaceutical (TY: 4502) supporting its Alzheimer’s disease program, and within Novartis (NOVN: VX) medical affairs.

Dr Nishi is a pharmacologist and translational scientist who has led multiple drug discovery programs in neurological disorders and other therapeutic areas. He joins Ovid from Takeda Pharmaceuticals, where he played a critical role in the invention and development of soticlestat, a small molecule inhibitor of cholesterol 24-hydroxylase.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK